Market OpportunityThe new indication significantly increases the company’s total addressable market (TAM), and could potentially accelerate adoption due to the expanded versatility of the device.
Regulatory ApprovalTNON's Catamaran SI Joint Fusion System received an expanded indication from the FDA for use in augmenting thoracolumbar fusion.
ValuationWith a significant market opportunity and superior technology, TNON is considered undervalued, supporting a Buy rating.